Today: 7 February 2026
Subscribe
Browse Category

NASDAQ:CAPR News 3 December 2025 - 4 December 2025

Capricor Therapeutics (CAPR) Soars After HOPE‑3 Win: Latest News, Analyst Targets and Stock Forecast as of December 4, 2025

Capricor Therapeutics (CAPR) Soars After HOPE‑3 Win: Latest News, Analyst Targets and Stock Forecast as of December 4, 2025

Updated: December 4, 2025 – mid‑day U.S. trading Capricor Therapeutics, Inc. (NASDAQ: CAPR) has just pulled off the kind of move small‑cap biotech traders dream about and risk managers lose sleep over. After releasing decisive Phase 3 data for its Duchenne muscular dystrophy (DMD) cell therapy Deramiocel, the stock has exploded several hundred percent in barely two trading sessions and is now hovering around $29.96 per share. The HOPE‑3 trial didn’t just “meet endpoints” in a boring, incremental way. It showed a 54% slowing of upper‑limb functional decline and 91% preservation of heart function versus placebo – in a disease
4 December 2025
··
Capricor Therapeutics (CAPR) Stock Skyrockets on HOPE‑3 Win: FDA Path, Price Targets and 2026 Outlook

Capricor Therapeutics (CAPR) Stock Skyrockets on HOPE‑3 Win: FDA Path, Price Targets and 2026 Outlook

Updated December 3, 2025 Capricor Therapeutics, Inc. (NASDAQ: CAPR) has just turned into one of the wildest biotech stories of 2025. After the company reported positive topline results from its pivotal Phase 3 HOPE‑3 trial of deramiocel in Duchenne muscular dystrophy (DMD) early Wednesday, CAPR stock exploded from roughly $6.36 at Tuesday’s close to around $30 in Wednesday’s trading — a move of about +380%, with intraday highs near $40 and gains at one point exceeding +500%. BioPharma Dive At the same time, Wall Street analysts, regulators and patient advocates are rapidly reassessing both the approval odds and the long‑term
3 December 2025
···
Capricor Therapeutics (NASDAQ: CAPR) Soars Over 500% After HOPE‑3 Phase 3 Win: What It Means for the Stock Now

Capricor Therapeutics (NASDAQ: CAPR) Soars Over 500% After HOPE‑3 Phase 3 Win: What It Means for the Stock Now

Capricor Therapeutics’ stock exploded higher on December 3, 2025 after the biotech announced that its pivotal Phase 3 HOPE‑3 trial of Deramiocel (CAP‑1002) in Duchenne muscular dystrophy (DMD) met both its primary and key secondary endpoints.GlobeNewswire Below is a deep dive into today’s news, the regulatory backdrop, the company’s finances and pipeline, and how analysts have been thinking about CAPR stock heading into this inflection point. Key Takeaways Capricor Stock Today: A Biotech Super‑Spike As of early afternoon on December 3, 2025, Capricor Therapeutics (NASDAQ: CAPR) was trading around $39–40 per share, up from approximately $6.36 at the previous close.
3 December 2025
···
Capricor Therapeutics (CAPR) Soars on Positive Phase 3 HOPE‑3 Results: Latest Stock News, Analyst Targets and 2025 Outlook

Capricor Therapeutics (CAPR) Soars on Positive Phase 3 HOPE‑3 Results: Latest Stock News, Analyst Targets and 2025 Outlook

Capricor Therapeutics, Inc. (NASDAQ: CAPR) is back in the spotlight on December 3, 2025, after announcing positive topline results from its pivotal Phase 3 HOPE‑3 trial of deramiocel (CAP‑1002) in Duchenne muscular dystrophy (DMD). The news has reignited hopes for eventual U.S. approval of the therapy and sent CAPR shares sharply higher in premarket trading.Capricor Therapeutics, Inc.+1 With Wall Street price targets implying several‑hundred‑percent upside from current levels, and a high‑stakes regulatory saga still unfolding after the FDA’s rejection earlier this year, CAPR has become one of the most closely watched small‑cap biotech stocks of late 2025.Reuters+2StockAnalysis+2 Below is a
3 December 2025

Stock Market Today

Kenvue stock price holds near $18 as Kimberly-Clark deal math tightens — what to watch next week

Kenvue stock price holds near $18 as Kimberly-Clark deal math tightens — what to watch next week

7 February 2026
Kenvue shares closed Friday at $18.13, up 0.33%, with about 63.5 million shares traded. The Kimberly-Clark offer values Kenvue at roughly $18.76 per share, leaving a deal spread of about 3%. Both companies’ shareholders approved the merger, which is expected to close in the second half of 2026 pending regulatory approvals. Kenvue’s dividend record date is Feb. 11, with earnings due Feb. 17.
Go toTop